Camurus stock
Price history
+20.34% over the period1 year: from kr 614.50 (November 20, 2025) to kr 739.50 (November 20, 2026), +20.34%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 739.50 |
| October 30, 2026 | kr 673.00 |
| September 30, 2026 | kr 624.50 |
| August 31, 2026 | kr 583.50 |
| July 31, 2026 | kr 617.50 |
| June 30, 2026 | kr 565.50 |
| May 29, 2026 | kr 526.50 |
| April 30, 2026 | kr 531.00 |
| March 31, 2026 | kr 467.00 |
| February 27, 2026 | kr 503.00 |
| January 30, 2026 | kr 667.50 |
| December 30, 2025 | kr 616.00 |
| November 28, 2025 | kr 617.00 |
| November 20, 2025 | kr 614.50 |
At a glance
The company
Develops and commercializes medicines for severe and chronic diseases including opioid dependence, pain, and metabolic and endocrine disorders
Latest results
Quarter to September 30, 2026 · EPS kr 4.53 (estimate kr 4.12)
TickerLandia's take on Camurus
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 60 vs a median of 75 over its last 4 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 59 vs 38 (+55%) in a group of 9.
- Strong point: Financial strength (86/100 in its group). Weak point: Earnings stability (58/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.40% from the 52-week high
Analysts · 7 analysts
Average targetkr 850.00+14.94% vs. price
Buy 7 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Camurus
Compared with similar companies: very high financial strength and very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh75
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 58.7 76 EV/EBITDA 43.5 74 Forward P/E 48.1 83 Price/book 8.85 73 Price/sales 18.2 71 Profitabilityhigh78
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 37.4% 83 Net margin 31.2% 81 ROE 16.6% 61 ROA 11.0% 83 Gross margin 93.2% 83 Earnings stabilityaverage58
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 23.0% 54 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +39.80% 71 Average revenue growth (3 years) +33.30% 62 Revenue growth (year over year) +27.70% 58 Financial strengthvery high86
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −4.06 96 Interest coverage 156.7 81 Debt/equitycounts in reverse: lower means more financial strength 0.02 79 Current ratio 9.65 88 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong82
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +20.34% 67 Distance from 200-day average +28.14% 97 Riskhigh67
How much the price swings.
Metric Value Position in group Volatility (60 days) 28.1% 52 Maximum drawdown (12 months) 37.9% 83
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Camurus is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Camurus's P/E today is 60.3, below the median of its last 4 fiscal years (75.1; between 50.2 and 260.4 from 2022 to 2025). Camurus's P/E (trailing 12 months): 58.7, +55% against the median of a group of 9 similar companies (38.0).
Compared with 9 similar companies
| Metric | Camurus | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 58.7 | Middle | |
| Forward P/E | 48.1 | Middle | |
| Operating margin | 37.4% | High | |
| ROE | 16.6% | Middle | |
| Debt/equity | 0.02 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Camurus. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 702.08M
Latest quarter · Q2 2026
Net income
kr 240.83M
Latest quarter · Q2 2026
Quarterly net margin
34.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 44.04B
- P/E
- 58.7
- EPS
- kr 12.60
- Volume
- 75.36K
- Daily trading
- €7.15M
- Dividend yield
- 0.00%
How Camurus is changing
All resultsRevenue grew 46.5% a year on average over the last 5 years
Operating margin rose from 7.5% to 39.1%
Profits turn into cash: free cash flow equal to 106% of net income
Returns
Camurus returns
kr 1,000 invested in Camurus 5 years ago, on November 22, 2021, would be worth kr 4,428 today: +342.81% in total, +34.71% per year. This is the price return only: dividends are excluded.
| Period | Camurus | kr 1,000 becomes |
|---|---|---|
| 1 month | +11.37% | kr 1,114 |
| 6 months | +37.97% | kr 1,380 |
| Year to date | +20.05% | kr 1,200 |
| 1 year | +20.34% | kr 1,203 |
| 3 years | +65.81% | kr 1,658 |
| 5 years | +342.81% | kr 4,428 |
| 10 years | +578.75% | kr 6,788 |
Price only, without dividends. Calculate your investment
The chart in detail
Camurus: technical analysis
Camurus is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.7% below its all-time closing high (kr 745.00, November 13, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +28.14%
Support and resistance
Price areas where Camurus has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 739.50
- Supportkr 698.83−5.50%3 touches, last on February 10, 2026
- Supportkr 659.00−10.89%2 touches, last on November 4, 2026
- Supportkr 642.50−13.12%5 touches, last on August 20, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 28.1%
- Largest fall in the last year
- −37.87%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Camurus: seasonality
Average monthly price change over 11 years
Over the last 11 years, the strongest month for Camurus has been April: +9.34% on average, positive in 6 years out of 11. The weakest has been October: −3.83% on average, positive in 3 years out of 11. November, the current month, has been positive in 6 years out of 10 (+8.09% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.89% | +1.08% | 6 of 11 |
| February | −2.02% | −5.96% | 4 of 11 |
| March | −1.64% | −3.35% | 5 of 11 |
| April | +9.34% | +2.39% | 6 of 11 |
| May | +3.39% | +3.65% | 6 of 11 |
| June | +5.60% | +3.35% | 8 of 11 |
| July | +6.71% | +9.20% | 7 of 11 |
| August | +1.97% | +0.88% | 6 of 11 |
| September | +5.63% | +5.71% | 7 of 11 |
| October | −3.83% | −1.59% | 3 of 11 |
| November | +8.09% | +4.52% | 6 of 10 |
| December | −3.33% | −4.04% | 2 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Camurus and its competitors
Based in Lund, Sweden, Camurus was founded in 1991 and works as a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases. Its marketed products include Buvidal, used for opioid dependence and chronic pain, and Brixadi, used for opioid use disorder. The pipeline covers chronic pain, acromegaly, prostate cancer, polycystic liver disease and rare genetic obesity disorders, with partnerships involving Braeburn Pharmaceuticals, Rhythm Pharmaceuticals and Eli Lilly. The company serves customers in Europe, Africa, the Middle East, North America and Asia.
- Headquarters
- Lund, Sweden
- Employees
- 323
- Founded
- 1991
- Chief executive
- Fredrik Tiberg
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| CamurusCAMX | $4.32B | 37.4% | 58.7 | +37.97% |
| ABIVAXABVX | $6.06B | -6,270.4% | — | −38.78% |
| Bachem HoldingBANB | $6.84B | 21.8% | 38.7 | −2.87% |
| Bavarian NordicBAVA | $2.72B | 18.1% | 12.7 | +24.00% |
| BioArcticBIOA.B | $2.66B | 19.6% | 259.5 | −6.59% |
| ALK-AbellóALK.B | $7.79B | 26.6% | 38.0 | −7.14% |
Same industry or related industries, similar size. Compare Camurus with its competitors · Full profile
